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Abstract
Background: To assess the risk of psychiatric disorders in Ehlers-Danlos syndrome (EDS) and hypermobility syndrome.
Methods: Nationwide population-based matched cohort study. EDS, hypermobility syndrome and psychiatric disorders
were identified through Swedish national registries. Individuals with EDS (n = 1,771) were matched with comparison
individuals (n = 17,710). Further, siblings to individuals with EDS who did not have an EDS diagnosis themselves were
compared with matched comparison siblings. Using conditional logistic regression, risk of autism spectrum disorder
(ASD), bipolar disorder, attention deficit hyperactivity disorder (ADHD), depression, attempted suicide, suicide
and schizophrenia were estimated. The same analyses were conducted in individuals with hypermobility syndrome
(n = 10,019) and their siblings.
Results: EDS was associated with ASD: risk ratio (RR) 7.4, 95 % confidence interval (95 % CI) 5.2–10.7; bipolar disorder:
RR 2.7, CI 1.5–4.7; ADHD: RR 5.6, CI 4.2–7.4; depression: RR 3.4, 95 % CI 2.9–4.1; and attempted suicide: RR 2.1, 95 % CI 1.
7–2.7, but not with suicide or schizophrenia. EDS siblings were at increased risk of ADHD: RR 2.1, 95 % CI 1.4–3.3;
depression: RR 1.5, 95 % CI 1.1–1.8; and suicide attempt: RR 1.8, 95 % CI 1.4–2.3. Similar results were observed for
individuals with hypermobility syndrome and their siblings.
Conclusions: Individuals with EDS and hypermobility syndrome are at increased risks of being diagnosed with
psychiatric disorders. These risk increases may have a genetic and/or early environmental background as suggested by
evidence showing that siblings to patients have elevated risks of certain psychiatric disorders.
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Background
Ehlers-Danlos syndrome (EDS) is the name applied to a
rather large group of inherited disorders that affect the
connective tissue, the tissue that provides support to
many parts of the body. This genetic disorder is present
in at least 1/5000 individuals [1] and an important cause
of joint hypermobility syndrome [2]. The disease is charac-
terized by hypermobility, although symptoms and signs can
be highly variable and include joint complaints, myalgia,
skin problems, sleep apnea, pneumothorax and cardiovas-
cular disease. While a diagnosis of EDS can be comforting
to the patient, there is no curative treatment for EDS.
Instead, physicians aim to stabilize joints and prevent
complications, sometimes using surgery to resolve the
condition. Physiotherapy is an integral part of patient
management [3].
Intense pain, diagnostic delay and risk of unemploy-
ment due to musculoskeletal complications, all contrib-
ute to the emotional burden of the disorder [4]. Already
in 1994, Lumley et al. reported a link between EDS and
psychological problems [5]. Despite the long-term
awareness of psychosocial dysfunctioning in EDS, studies
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on psychiatric disorders in EDS or hypermobility syn-
drome are rare, but well summarized in a recent meta-
analysis by Smith et al. [4]. Smith et al. found a fourfold
increased risk of both anxiety and depression in hyper-
mobility syndrome, while the risk of panic disorder was
even higher (odds ratio (OR) = 6.7, 95 % confidence
interval (95 % CI) 2.2–20.4). However, the OR for anx-
iety was based on only 253 patients with joint hypermo-
bility and the three studies [6–8] contributing data on
anxiety found substantially different risk estimates with
the most recent paper reporting a lack of association but
with wide CIs (OR = 0.9, 95 % CI 0.1–5.6) [7]. Examining
anxiety scores, levels were higher in the 501 individuals
with joint hypermobility (standardized mean difference
in score: +0.5) than in the 948 controls [4].
Further, other psychiatric disorders have been impli-
cated in EDS [9]. Depression [6, 7, 10] has been linked
to joint hypermobility (OR 4.1, 95 % CI 1.8–9.4) [4], but
studies have been small and study participants may not
have reflected the average patient with EDS or hypermo-
bility syndrome. One study found a striking occurrence
of depression in EDS (69 % of the patients had a record
of depression) [11].
While we are unaware of any research in EDS and
schizophrenia, there are several case reports of an asso-
ciation between the EDS-like Marfan Syndrome and
schizophrenia [12]. Similarly, there are case reports of
EDS and autism spectrum disorders (ASDs) [4, 13], but
to our knowledge no case–control or cohort studies
exist on the topic.
Given the inconsistent and sometimes flawed data on
EDS, hypermobility syndrome and psychiatric disorder,
we decided to conduct a population-based matched cohort
study examining ASD, bipolar disorder, ADHD, depression,
suicide attempt, completed suicide and schizophrenia in
patients with EDS or hypermobility syndrome. We also
examined the same psychiatric disorders in siblings to pa-
tients with EDS or hypermobility syndrome. If both EDS/
hypermobility patients and their siblings are at increased
risk of psychiatric disorders this suggests that genetic and/
or early environmental factors influence the association
with psychiatric disorders.
Methods
Using the Swedish Patient Registry [14], we identified indi-
viduals with EDS and hypermobility syndrome. Moreover,
through the Multi-Generation Registry we identified sib-
lings to patients with EDS and hypermobility syndrome
and their respective comparison siblings.
EDS and hypermobility syndrome
Individuals with EDS were defined according to the
relevant international classification of disease (ICD-10)
code in the Swedish Patient Registry (Q79.6). We also
examined hypermobility syndrome (ICD-10: M35.7).
The Swedish Patient Registry started in 1964 and be-
came nationwide in 1987. Only in 1997 with the intro-
duction of ICD-10 (as opposed to ICD-9, which was
used between 1987 and 1996) were there specific codes
for EDS and hypermobility syndrome. While we are
unaware of any validation of these two diagnoses, most
chronic diagnoses have a positive predictive value of
85–95 % in the Patient Registry [14]. Only the first
record of either EDS or hypermobility syndrome was
used and hence double entries were removed.
Psychiatric disorders
The outcome measures were the following psychiatric
disorders: bipolar disorder (defined according to a vali-
dated algorithm [15], ASD (ICD-10: F84), ADHD (ICD-
10: F90), depression (ICD-8: 296.0, 300.4, ICD-9: 296B,
300E, 311, ICD-10: F32-33, F34.1, F34.8-9, F38.1),
schizophrenia (ICD-8: 295.0-6, 295.8-9, ICD-9: 295A-G,
295W, 295X; ICD-10: F20), suicide attempt (ICD-10:
X60-84, Y10-34) and completed suicide (defined via the
Cause of Death Registry). ASD was also identified via
the Clinical Registry for Child and Adolescent Psychiatry
in Stockholm County [16] (ICD-10: F84 and DSM-IV:
299). This latter registry was also used for ADHD (ICD-
10: F90 and DSM-IV: 314). To maximize coverage, we
employed the Prescribed Drug Registry for ADHD in
which cases were defined through treatment with stimu-
lant (amphetamine, dexamphetamine, methylphenidate)
or non-stimulant medication (atomoxetine).
Psychiatric disorders have been recorded in the Patient
Registry since 1973 [14]. Most validation studies of psychi-
atric disorders in the Patient Registry have concerned
schizophrenia, frequently indicating a positive predictive
value of about 90 % [17–19]. Although carried out in neigh-
boring Denmark, a recent validation of ASD in 499 patients
found that 469 fulfilled stipulated diagnostic criteria (equal
to a positive predictive value of 94.3 %) [20]. The Patient
Registry is maintained by the Swedish National Board of
Health and Welfare (http://www.socialstyrelsen.se/english).
This registry has recorded inpatient care since 1964 (with
psychiatric care added in 1973) [14]. Diseases are coded
using ICD codes and for each healthcare contact several
items are recorded, including personal identity number
(PIN) [21], date of admission and discharge, hospital and
primary and secondary diagnoses. Through the unique
PIN, information on each individual patient can be linked
to other registries. Additional file 1: Table S1 outlines the
number of patients with each included outcome by the
respective registries used for identification.
Study participants
Each individual with EDS or hypermobility syndrome
was matched with up to 10 comparison individuals for
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same sex, age and county of residence at the year of first
diagnosis. Comparison individuals were retrieved from
the Total Population Registry [22]. Through this register,
we also identified all siblings to our EDS and hypermo-
bility syndrome patients (hereafter referred to as “EDS
siblings” and “hypermobility syndrome siblings”, respect-
ively) and all siblings to comparison individuals without
EDS and hypermobility syndrome, matched on birth year
and sex (hereafter referred to as “comparison siblings”).
The part of the Total Population Registry containing data
on siblings is usually called “The Multi-Generation Regis-
try”. This Registry contains data on 97 % of the mothers
and 95 % of the fathers of index persons. Index persons are
restricted to individuals alive on 1 January 1961 and born
in 1932 or later [23].
Statistical analyses
To estimate risks of psychiatric disorders in individuals
with EDS or hypermobility syndrome and their siblings,
we calculated risk ratios (RR) and 95 % CIs using condi-
tional logistic regression. In the sibling analyses, CIs
were obtained with a robust sandwich estimator to ad-
just for the correlated data structure. In addition, we
conducted a secondary analysis restricted to individuals
born in Sweden to rule out the possibility that an associ-
ation with psychiatric disorders would be due to country
of birth (as a proxy for ethnicity). In two post-hoc ana-
lyses we examined the risk of psychiatric disorders (1)
according to age at onset of EDS (≤19 years vs. ≥20
years), and (2) when only considering psychiatric disor-
ders occurring after first EDS diagnosis.
Statistical analyses were conducted in SAS version 9.4
(SAS Institute, Cary, NC, USA)., and the STROBE
guidelines for the reporting of observational studies
were followed.
Results
We identified 1,780 individuals with EDS (74 % females),
1,722 EDS siblings, 10,019 individuals with hypermobility
syndrome (67 % females) and 11,082 hypermobility syn-
drome siblings. The vast majority of individuals with EDS
(94 %) and hypermobility syndrome (92 %) were born in
Sweden. Nine individuals with EDS (0.005 %) were ex-
cluded from the analyses because of missing demographic
data (remaining: n = 1,771). Additional demographic data
are given in Additional file 2: Table S2.
EDS vs. comparison individuals
In all, 52 (2.9 %) EDS patients and 72 (0.4 %) compari-
son individuals were diagnosed with ASD (RR 7.4, 95 %
CI 5.2–10.7, Table 1). Bipolar disorder was diagnosed in
15 (0.9 %) vs. 56 (0.3 %) comparison individuals (RR 2.7,
95 % CI 1.5–4.7), ADHD in 76 (4.3 %) vs. 144 (0.8 %)
(RR 5.6, 95 % CI 4.2–7.4), depression in 197 (11.1 %) vs.
643 (3.6 %) (RR 3.4, 95 % CI 2.9–4.1) and 96 (5.4 %) vs.
464 (2.6 %) attempted suicide (RR 2.1, 95 % CI 1.7–2.7).
Restricting our data to individuals with EDS that pre-
ceded psychiatric disorder, we found positive associa-
tions with ASD and ADHD but an inverse relationship
with attempted suicide (Additional file 3: Table S3).
EDS siblings vs. comparison siblings
ADHD (RR 2.1, 95 % CI 1.4–3.3), depression (RR 1.5, 95 %
CI 1.1–1.8) and suicide attempt (RR 1.8, 95 % CI 1.4–2.3)
were more frequently diagnosed in siblings to EDS patients
than in comparison siblings.
Hypermobility syndrome vs. comparison individuals
Of the hypermobility syndrome patients, 161 (1.6 %) vs.
1,186 (1.2 %) comparison individuals were diagnosed
with ASD (RR 1.4, 95 % CI 1.1–1.6; Table 3). Bipolar
disorder was diagnosed in 42 (0.4 %) vs. 296 (0.3 %)
comparison individuals (RR 1.4, 95 % CI 1.1–2.0),
ADHD in 301 (3.0 %) vs. 546 (0.5 %) (RR 5.8, 95 % CI
5.0–6.7), Depression in 696 (7.0 %) vs. 3,180 (3.2 %) (RR
2.3, 95 % CI 2.1–2.5) and attempted suicide in 423 (4.2 %)
vs. 2,121 (2.2 %) (RR 2.1, 95 % CI 1.8–2.3).
Table 1 Risks of psychiatric disorders, suicide attempt and suicide in individuals with EDS compared with matched comparison
individuals
EDS individuals (n = 1,771) Matched comparison individuals (n = 17,710)
n (%) n (%) RR (95 % CI) RRa (95 % CI)
Autism spectrum disorder 52 (2.9) 72 (0.4) 7.4 (5.2–10.7) 8.4 (5.7–12.4)
Bipolar disorder 15 (0.9) 56 (0.3) 2.7 (1.5–4.7) 2.6 (1.4–4.7)
ADHD 76 (4.3) 144 (0.8) 5.6 (4.2–7.4) 5.8 (4.3–7.9)
Depression 197 (11.1) 643 (3.6) 3.4 (2.9–4.1) 3.5 (2.9–4.2)
Suicide attempt 96 (5.4) 464 (2.6) 2.1 (1.7–2.7) 2.1 (1.6–2.6)
Suicide 2 (0.1) 6 (0.03) 3.3 (0.7–16.5) 2.9 (0.6–14.4)
Schizophrenia 3 (0.2) 38 (0.2) 0.8 (0.2–2.6) 0.6 (0.1–2.5)
Associations are expressed as risk ratios (RR) and 95 % confidence intervals (95 % CIs) from conditional logistic regression
Note: statistically significant RR are bolded. RRa, risk ratios restricted to individuals born in Sweden
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Hypermobility syndrome siblings vs. comparison siblings
ASD (RR 1.3, 95 % CI 1.1–1.7), ADHD (RR 1.3, 95 % CI
1.1–1.5), depression (RR 1.2, 95 % CI 1.1–1.3) and suicide
attempt (RR 1.2, 95 % CI 1.1–1.4) were more often diag-
nosed in hypermobility syndrome siblings as compared
with comparison siblings (Table 4).
Sensitivity analyses
In the analyses restricted to individuals born in Sweden,
all associations remained virtually unchanged, except that
the association between hypermobility syndrome and
bipolar disorder was no longer statistically significant
(Tables 2, 3 and 4).
Finally, we found similar risk estimates for psychiatric
disorders in EDS patients diagnosed in childhood and
adulthood; however, lack of statistical power did not
allow estimation of risks of some psychiatric disorders in
individuals with EDS aged ≤19 years at their first diagno-
sis (Additional file 4: Table S4).
Discussion
In this nationwide population-based cohort study, we ex-
amined EDS, hypermobility syndrome and risk of psychi-
atric disorders. We found a substantially increased risk of
several psychiatric disorders in addition to depression [4].
Our cohort of hypermobility syndrome patients was
about forty times larger than the total number of hyper-
mobility patients included in a recent meta-analysis [4]
(our study included 10,019 individuals with hypermobility
syndrome vs. 238 hypermobility patients and depression
in Smith et al.). The large number of study participants
allowed for the calculation of precise risk estimates.
Furthermore, our study is the first to examine psychi-
atric disorders in first-degree relatives to persons with
EDS and hypermobility syndrome. This aspect of the
study is important in that we were able to demon-
strate that familial factors play an important role in
the psychiatric comorbidity in EDS and hypermobility
syndrome.
Comparison with the previous literature
Since the 1990s, at least three papers have examined the
association between hypermobility syndrome and EDS and
anxiety [6–8]. Together, they point towards a significant
association between hypermobility syndrome and anxiety.
Similarly, some research [6], but not all [7], suggests a posi-
tive association with depression. However, most of these
studies have been small.
One Spanish study found a 10-fold increased risk of
panic disorders in patients with hypermobility syndrome
[6]. The same authors recently reported that hypermo-
bility was linked to a 22-fold increased risk of panic/
agoraphobia disorders and a 4-fold increase in the use of
anxiolytic drugs in patients with hypermobility [10]. How-
ever, more than 20 % of the study participants developed
hypermobility syndrome [10], limiting the external validity
of the findings.
Of note we found a protective effect of earlier EDS on
later suicide attempt in one of our post hoc analyses.
We believe this is a chance finding although we cannot
rule out that some individuals take comfort in receiving
a diagnosis (EDS) for which they may have sought help
for many years.
Our findings confirm previous evidence of positive asso-
ciations with psychiatric disorders but also contribute new
knowledge. First, our population-based approach maxi-
mizes statistical power and minimizes selection bias. In
contrast, past research has often been based on patients
attending tertiary centers. Such patients generally have a
more severe disease than the average patient and this
might overestimate risk estimates.
We used the Patient Registry [14] to identify individ-
uals with EDS, hypermobility syndrome and psychiatric
disorder. This Registry has been extensively validated with
a positive predictive value for most chronic disorders ran-
ging from 85–95 %. However, neither EDS nor hypermobil-
ity syndrome has been validated per se in this study. In
addition, we lacked information on the Beighton score for
hypermobility, presence of pain or number of complaints.
Table 2 Risks of psychiatric disorders, suicide attempt and suicide in siblings of individuals with EDS (EDS siblings), compared with
matched siblings to individuals without EDS (comparison siblings)
EDS siblings (n = 1,722) Comparison siblings (n = 16,920)
n (%) n (%) RR (95 % CI) RRa (95 % CI)
Autism spectrum disorder 10 (0.6) 56 (0.4) 1.8 (0.9–3.4) 1.7 (0.9–3.2)
Bipolar disorder 7 (0.5) 69 (0.4) 1.0 (0.5–2.0) 0.9 (0.4–2–0)
ADHD 26 (1.5) 123 (0.7) 2.1 (1.4–3.3) 2.1 (1.4–3.3)
Depression 72 (4.2) 492 (2.9) 1.5 (1.1–1.8) 1.4 (1.1–1.8)
Suicide attempt 66 (3.8) 364 (2.1) 1.8 (1.4–2.3) 1.8 (1.4–2.3)
Suicide 10 (0.6) 44 (0.3) 2.1 (1.2–3.9) 2.3 (1.3–4.1)
Schizophrenia 7 (0.4) 54 (0.3) 1.3 (0.6–2.7) 1.4 (0.6–3.1)
Associations are expressed as risk ratios (RR) and 95 % confidence intervals (95 % CIs) from conditional logistic regression
Note: statistically significant RR are bolded. RRa, risk ratios restricted to individuals born in Sweden
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Hence, we were unable to predict the risk of psychiatric co-
morbidity according to EDS or hypermobility phenotype.
Nor did we have any clinical data (e.g., skin biopsy data) on
patients and hence could not estimate what proportion of
patients had, for instance, abnormal bruising or bleeding,
etc. Further, the Swedish Patient Registry does not distin-
guish between various forms of EDS, and we were unable
to examine psychiatric disorders and EDS divided into clas-
sical (type I) or vascular (type IV) or according to the newer
Villefranche Classification of EDS [2]. Another weakness is
that we only had data on EDS and hypermobility syndrome
in a hospital-based setting. The Swedish Patient Registry
does not record visits to general practitioners. Thus, it
may be that the majority of patients with hypermobil-
ity syndrome and EDS are cared for in a non-hospital
outpatient setting. At the same time, the diagnosis
often requires a certain amount of investigation that is
usually done in a hospital (typically with a rheumatolo-
gist) to avoid differential diagnosis misclassification.
Such a work-up would likely result in a diagnosis in
the Patient Registry.
We are unaware of any studies on EDS, hypermo-
bility syndrome and ADHD. ADHD is associated with
the risk of psychiatric and functional problems [24]
that inevitably leads to serious consequences for the
affected individuals, their families and society [24, 25].
Prevalence estimates in children (≈5 %) [26] and adults
(≈2–5 %) [27] further underscore the societal impact of
the disorder.
The association seen in this study may depend on sev-
eral mechanisms, and not necessarily the same mecha-
nisms for all psychiatric disorders. The disease load in
hypermobility syndrome and EDS may contribute to a
lower quality of life and an increased risk of depression
and suicide attempt, but is less likely to explain the
excess risk of other disorders such as ASD and bipolar
disorder. An increased disease burden is otherwise likely
to occur both before (diagnostic delay with secondary
Table 3 Risks of psychiatric disorders, suicide attempt and suicide in individuals with hypermobility syndrome (including EDS)
compared with matched comparison individuals
Hypermobility syndrome individuals
(n = 10,019)
Matched comparison individuals
(n = 100,190)
n (%) n (%) RR (95 % CI) RRa (95 % CI)
Autism spectrum disorder 161 (1.6) 1,186 (1.2) 1.4 (1.1–1.6) 1.3 (1.1–1.6)
Bipolar disorder 42 (0.4) 296 (0.3) 1.4 (1.1–2.0) 1.4 (0.9–1.9)
ADHD 301 (3.0) 546 (0.5) 5.8 (5.0–6.7) 5.5 (4.8–6.4)
Depression 696 (7.0) 3,180 (3.2) 2.3 (2.1–2.5) 2.3 (2.1–2.5)
Suicide attempt 423 (4.2) 2,121 (2.2) 2.1 (1.8–2.3) 2.0 (1.8–2.3)
Suicide 6 (0.1) 3 (0.05) 1.8 (0.8–4.4) 1.9 (0.7–5.0)
Schizophrenia 11 (0.1) 159 (0.2) 0.7 (0.4–1.3) 0.7 (0.4–1.3)
Associations are expressed as risk ratios (RR) and 95 % confidence intervals (95 % CIs) from conditional logistic regression
Note: statistically significant RR are bolded. RRa, risk ratios restricted to individuals born in Sweden
Table 4 Risks of psychiatric disorders, suicide attempt and suicide in siblings of individuals with hypermobility syndrome
(hypermobility syndrome siblings) compared with matched siblings to individuals without hypermobility syndrome
(comparison siblings)
Hypermobility syndrome siblings
(n = 11,082)
Comparison siblings
(n = 108,772)
n (%) n (%) RR (95 % CI) RRa (95 % CI)
Autism spectrum disorder 66 (0.6) 500 (0.5) 1.3 (1.1–1.7) 1.3 (1.1–1.7)
Bipolar disorder 31 (0.3) 269 (0.3) 1.1 (0.8–1.6) 1.2 (0.8–1.7)
ADHD 124 (1.1) 966 (0.9) 1.3 (1.1–1.5) 1.3 (1.1–1.5)
Depression 343 (3.1) 2,788 (2.6) 1.2 (1.1–1.3) 1.2 (1.1–1.3)
Suicide attempt 270 (2.4) 2,182 (2.0) 1.2 (1.1–1.4) 1.2 (1.1–1.4)
Suicide 29 (0.3) 230 (0.2) 1.2 (0.9–1.7) 1.3 (0.9–1.8)
Schizophrenia 26 (0.2) 184 (0.2) 1.4 (0.9–2.0) 1.3 (0.9–1.9)
Associations are expressed as risk ratios (RR) and 95 % confidence intervals (95 % CIs) from conditional logistic regression
Note: statistically significant RR are bolded. RRa, risk ratios restricted to individuals born in Sweden
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patient frustration is common in EDS) and after diag-
nosis (there is no curative treatment for EDS). Hyper-
mobility syndrome, EDS and some psychiatric disorders
may also share common familial risk factors. Relative to
risk factors, of particular interest is our finding of an
increased risk of psychiatric disorder in unaffected EDS
or hypermobility syndrome siblings. This finding sug-
gests that it is not only the disease itself that links to
psychiatric disorder but also that part of the risk in-
crease may be due to shared genetic or early environ-
mental influences.
Among the weaknesses of this study are the limited
data on clinical phenotypes such as symptoms and signs
of disease of the Patient Registry. While the specificity of
this register is high [14], especially for chronic disorders
(including EDS or hypermobility syndrome), the sensitivity
may be lower. Hence, we cannot ignore the possibility that
some cases may have been missed. If such cases have less
psychiatric comorbidity than individuals recorded with
EDS or hypermobility in the Patient Registry, we may
have overestimated the risk of psychiatric morbidity.
However, considering the low prevalence of EDS or
hypermobility syndrome in the general population (1/
5000), false-negatives cases are unlikely to influence
our estimates more than marginally.
Finally, we cannot preclude that surveillance bias in
patients with EDS or hypermobility syndrome and in
their siblings has contributed to the higher risks for
psychiatric disorder, even though the elevated risks ob-
served in unaffected siblings argue against a substantial
effect of surveillance bias in this study.
Conclusion
In summary, this is the largest study to date to examine
the association between EDS, hypermobility syndrome and
psychiatric disorders. A positive association between these
disorders confirms earlier case reports and smaller studies.
The relative risks for several psychiatric disorders were
substantial. Because siblings without EDS or hypermobility
syndrome carried an increased risk of being diagnosed with
a psychiatric disorder, we suspect that these associations
may be due to genetic and shared environmental factors.
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